Polivy (polatuzumab vedotin)

pCPA File Number: 23194

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with R-CHP for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL.

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0397-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable